Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy

No Thumbnail Available
File version
Author(s)
Nightingale, James
Lum, Benedict
Ladwa, Rahul
Simpson, Fiona
Panizza, Benedict
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
License
Abstract

The natural history of adenoid cystic carcinoma (ACC) is relentless, defined by treatment failure heralded by locoregional recurrence and distant metastatic disease. In this review, we present an update of clinical features, molecular classification, current targeted therapies, immune landscapes and novel treatment targets with their respective clinical trials. The presented results are defined by a lack of overall response rate and limited progression free survival, with restriction to stable disease. In addition, ACC is resistant to immune checkpoint inhibition due to low tumour immunogenicity and lack of PD-L1 expression. Here we present a new prospective research paradigm for ACC, including the potential to target prostate specific membrane antigen (PSMA) and the potential for manipulation of target receptors in the clinic. The presentation of this review aims to promote future research to improve response rates and outcomes for therapeutics undergoing clinical trial in ACC.

Journal Title

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

Conference Title
Book Title
Edition
Volume

1875

Issue

2

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Oncology and carcinogenesis

Science & Technology

Life Sciences & Biomedicine

Biochemistry & Molecular Biology

Biophysics

Persistent link to this record
Citation

Nightingale, J; Lum, B; Ladwa, R; Simpson, F; Panizza, B, Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021, 1875 (2), pp. 188523

Collections